Skip to Main Content

Rise and shine, everyone, another steamy day is on the way. Yes, a heat wave continues to envelop the Pharmalot campus, where the shortest person is sleeping in and the official mascots are already exhausted. As for us, we are quaffing cups of stimulation and revving up the cooling machine. There is, after all, a lot to be done. So time to get cracking. Here are some tidbits. Hope your day is productive …

An execution drug obtained by Arkansas prison officials earlier this month appears to have been made by a Pfizer subsidiary, even though the drug maker said it doesn’t want its medicines used for executions, the Associated Press reports. The sale of vecuronium bromide by an unknown third party illustrates how difficult it can be for companies to prevent such sales in states like Arkansas that have execution secrecy laws.


Kadmon, a biotech started by Sam Waksal, plans to raise $100 million in a public offering this week, despite a leaky balance sheet and the notoriety of its founder, STAT tells us. Waksal, you may recall, scaled biotech heights thanks to the Erbitux cancer treatment marketed by one of his previous ventures, ImClone Systems. But he was later convicted in an infamous insider trading case that also ensnared one of his pals, television show host Martha Stewart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.